Revenue: As of FY2025 Q2, the actual value is USD 62.22 M.EPS: As of FY2025 Q2, the actual value is USD -0.06.<h4>Segment Revenue</h4><ul><li>Total Revenue: Increased 23% year-over-year to $62.2 million, driven by a 30% increase in telehealth revenue.</li><li>Telehealth Revenue: Increased 30% to $48.6 million.</li><li>WorkSimpli Revenue: Increased 3% to $13.7 million.</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: GAAP net loss was $2.9 million or - $0.06 per share, compared to a net loss of $7.7 million or - $0.19 per share in the prior-year period.</li><li>Gross Margin: 88%, compared to 90% in the prior-year period due to revenue mix.</li><li>Adjusted EBITDA: Increased 223% to $7.1 million, compared to $2.2 million in the prior-year period.</li><li>Telehealth Adjusted EBITDA: Increased 560% to $3.4 million, compared to $0.5 million in the prior-year period.</li></ul><h4>Cash Flow</h4><ul><li>Operating Cash Flow: Generated more than $8 million of operating cash flow.</li><li>Cash Position: Exited the quarter with $36.2 million in cash, inclusive of paying down $2.1 million of senior debt during the quarter.</li></ul><h4>Unique Metrics</h4><ul><li>Active Telehealth Subscribers: Increased 16% to approximately 297,000 at quarter-end.</li></ul><h4>Outlook / Guidance</h4><ul><li>Third Quarter 2025 Guidance: Total revenue expected in the range of $61 million to $63 million, with telehealth revenue in the range of $48 million to $50 million.</li><li>Full Year 2025 Guidance: Total revenue expected in the range of $250 million to $255 million, revised from previous guidance of $268 million to $275 million.</li><li>Telehealth Adjusted EBITDA: Forecasted to be in the range of $14 million to $16 million, down from $21 million previously.</li></ul>

LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 8-K: FY2025 Q2 Revenue: USD 62.22 M